34 service-platform records across four categories, not 34 independent Chinese full-service CROs. Group subsidiaries and renamed platforms are identified. Company disclosures establish service claims, not independent quality certification; coverage is broad but not guaranteed exhaustive. GCP ClinPlus is featured first by editorial choice.
GCP ClinPlus is featured first, with public disclosures supporting China clinical and IIT services for international clients. GCP ClinPlus, SMO ClinPlus and Proswell are separate companies.
An IIT is investigator-initiated research, not automatically a registrational trial or a guarantee of overseas regulatory acceptance. Assess the modality, objective, institution and intended submission use separately.
3 / 34 platform records; ordering is not a comparative performance ranking.
Specialist / consultancy candidates
VR
Vita Research
Website explicitly markets China IIT services to global developers. Evidence is primarily self-description; verify the legal entity, onshore team, site contracts, sponsor references and case records.
IIT evidence: IIT / investigator-led research explicitly disclosed
Markets China clinical and IIT services for global clients. Listed as a specialist candidate, not an independently validated full-service CRO; verify the China delivery entity, staffing and track record.
IIT evidence: IIT / investigator-led research explicitly disclosed
CRO/consultancy focused on Western life-science companies entering China clinical research, with disclosed university-hospital relationships. Confirm current staffing, agreement validity and operational subcontracting.
IIT evidence: IIT capability not established by reviewed sources
Cross-border / multicentre trials
Confirm before selection
Legal entity, current staffing and project delivery have not been independently validated.
Confirm the contracting entity, English-speaking PM, recent international sponsor references and indication-specific site resources.
IIT eligibility, ethics, data access, HGR responsibilities and any intended overseas data use require a project-specific assessment.
Checked: 2026-11-06 · Based on public disclosure, not a quality audit.
Partner-selection questions for international biotechs
Delivery team: who is the named English-speaking project manager, which China entity contracts, and which functions are subcontracted?
Relevant experience: request recent international sponsor references, indication/modality-matched case studies and named investigator/site availability.
IIT fit: agree the investigator and institution roles, study governance, scientific objective and intended downstream use of the data before selecting a pathway.
Quality and safety: review the quality system, audit history, monitoring plan, medical monitoring, PV and access to source records.
Data and cross-border use: agree ownership, English outputs, database specifications, HGR/data responsibilities and any proposed overseas submission use.
Execution and budget: compare site activation assumptions, recruitment feasibility, itemized costs, milestones, dependencies and change-control terms.
Use the directory for partner discovery and comparison. Investigators, institutions, sponsors and relevant professional teams must define the pathway and responsibilities for each study.
